search
Back to results

Noninferiority Comparison of Prophylactic Open Fracture Antimicrobial Regimens

Primary Purpose

Open Fracture, Post-Op Wound Infection

Status
Terminated
Phase
Phase 4
Locations
United States
Study Type
Interventional
Intervention
Ceftriaxone
Ampicillin/sulbactam
Piperacillin/tazobactam
Cefazolin + Gentamicin
Clindamycin + Gentamicin
Sponsored by
Mercy Health Ohio
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional prevention trial for Open Fracture focused on measuring Open Fracture, Wound Infection, Antimicrobial Prophylaxis, Cefazolin, Gentamicin, Ceftriaxone, Ampicillin/Sulbactam, Clindamycin, Piperacillin/tazobactam

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Age great than/equal to 18 years
  • Diagnosis of Grade III open fracture

Exclusion Criteria:

  • Water-borne injury
  • Farm-related injury

Sites / Locations

  • St. Joseph Warren Hospital
  • St. Elizabeth Youngstown Hospital

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm 4

Arm 5

Arm Type

Active Comparator

Active Comparator

Active Comparator

Active Comparator

Other

Arm Label

Cefazolin + Gentamicin

Ceftriaxone

Ampicillin/Sulbactam

Piperacillin/Tazobactam

Clindamycin + Gentamicin

Arm Description

[Cefazolin] Initial dose: Cefazolin 2g IV x1 dose (patient weight < 120kg) Cefazolin 3g IV x1 dose (patient weight >/= 120kg) Subsequent dose: Cefazolin 2g IV every 8 hrs (CrCl >/= 40 mL/min) Cefazolin 2g IV every 12 hrs (CrCl 20-39 mL/min) Cefazolin 2g IV every 24 hrs (CrCl < 20 mL/min) Duration: 24 hrs post-op after soft tissue coverage or total of 72 hrs, whichever comes first [Gentamicin] Initial dose: If Patient age </= 80 years old: 5 mg/kg adjusted body weight x1 dose (Max dose 500 mg) If Patient age >80 years old: 3 mg/kg adjusted body weight x1 dose (Max dose 300 mg) Subsequent dose: Pharmacy Consult to dose gentamicin Duration: 24 hrs post-op after soft tissue coverage or total of 72 hrs, whichever comes first

Initial dose: Ceftriaxone 2g IV x1 dose Subsequent dose: Ceftriaxone 2g IV every 24 hours Duration: One dose post-op after soft tissue coverage or total of 72 hours, whichever comes first

Initial dose: Ampicillin/Sulbactam 3g IV x1 dose Subsequent dose: Ampicillin/Sulbactam 3g IV every 6 hours (CrCl >/= 30 mL/min) Ampicillin/Sulbactam 3g IV every 12 hours (CrCl 15-29 mL/min) Ampicillin/Sulbactam 3g IV every 24 hours (CrCl <15 mL/min) Duration: 24 hours post-op after soft tissue coverage or total of 72 hours, whichever comes first

Initial dose: Piperacillin/Tazobactam 4.5g IV x1 dose over 30 minutes Subsequent dose: Piperacillin/Tazobactam 3.375g IV every 8 hours over 4 hours (CrCl >/= 20 mL/min) Piperacillin/Tazobactam 3.375g IV every 12 hours over 4 hours (CrCl < 20 mL/min) Duration: 24 hours post-op after soft tissue coverage or total of 72 hours, whichever comes first

Patients with known Penicillin allergy will receive: [Clindamycin] Initial dose: Clindamycin 900mg IV x1 dose Subsequent dose: Clindamycin 600mg IV every 8 hours Duration: 24 hours post-op after soft tissue coverage or total of 72 hours, whichever comes first [Gentamicin] Initial dose: If Patient age </= 80 years old: 5 mg/kg adjusted body weight x1 dose (Max dose 500 mg) If Patient age >80 years old: 3 mg/kg adjusted body weight x1 dose (Max dose 300 mg) Subsequent dose: Pharmacy Consult to dose gentamicin Duration: 24 hours post-op after soft tissue coverage or total of 72 hours, whichever comes first

Outcomes

Primary Outcome Measures

Post-surgical site wound infections
The primary outcome for this study is the number of post-surgical site wound infections, defined as initiation of antibiotics for surgical-site infection and/or need for surgical debridement of site. The acceptable infection rate per Trauma Practice Management Guidelines states a rate less than 20%.

Secondary Outcome Measures

Incidence of acute kidney injury
Incidence of acute kidney injury during hospital admission will be collected and compared to the other antibiotic regimens. Acute kidney injury is defined as (per KDIGO guidelines): An increase in SCr by 0.3 mg/dL within 48 hours OR Increase in SCr to 1.5 times baseline within the previous 7 days OR Urine volume less than 0.5 mL/kg/h for 6 hours
Average cost of antibiotic therapy per patient
Cost per patient of each antibiotic therapy will be calculated and compared to the other antibiotic regimens
Time to antibiotic therapy
Time from arrival to receiving first dose of antibiotic therapy will be collected (Goal within 30 minutes of arrival).

Full Information

First Posted
June 6, 2018
Last Updated
September 9, 2020
Sponsor
Mercy Health Ohio
search

1. Study Identification

Unique Protocol Identification Number
NCT03560232
Brief Title
Noninferiority Comparison of Prophylactic Open Fracture Antimicrobial Regimens
Official Title
A Randomized Controlled Trial Assessing Noninferiority of Three Antimicrobial Regimens for the Treatment of Grade III Open Fractures
Study Type
Interventional

2. Study Status

Record Verification Date
September 2020
Overall Recruitment Status
Terminated
Why Stopped
Unable to recruit patients in a timely fashion and unable to recruit sufficient patients
Study Start Date
July 9, 2018 (Actual)
Primary Completion Date
February 19, 2020 (Actual)
Study Completion Date
February 19, 2020 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Mercy Health Ohio

4. Oversight

Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Product Manufactured in and Exported from the U.S.
Yes

5. Study Description

Brief Summary
To demonstrate noninferiority of three different empiric antimicrobial regimens compared to the traditional antimicrobial regimen for the management of grade III open fractures as well as evaluate outcomes among these groups.
Detailed Description
Per the EAST practice management guidelines, an open fracture is defined as one in which the fracture fragments communicate with the environment through a break in the skin. The presence of an open fracture, either isolated or as part of a multiple injury complex, increases the risk of infection and soft tissue complications. Open fractures are further classified into Grade I - Grade III fractures per the Gustilo Classification. Grade III fractures are those with the highest likelihood of contamination and infection with infection rates ranging from 10% to 42%. EAST guidelines currently recommend systemic gram positive coverage for all open fractures with the addition of gram negative coverage for all Grade III fractures. Antibiotics should be initiated as soon as possible following the injury and should be continued for 72 hours after the injury or not greater than 24 hours after soft tissue coverage was obtained. Traditionally, patients received the combination of Cefazolin and Gentamicin as the preferred prophylactic antibiotic regimen, despite the need for multiple antibiotics and the risk of nephrotoxicity associated with aminoglycosides. Whether there is clinically a more ideal prophylactic antibiotic available remains to be seen. This proposed research initiative is intended to evaluate several antibiotic regimens with similar spectrums of activity to see if there is an equally effective single agent with minimal nephrotoxicity associated with its use. In selecting the study antibiotics to be utilized in the protocol, available information was obtained regarding timing of antibiotics, organisms identified by culture results, and any studies available on specific antibiotic regimens. In regards to timing, there is evidence to support that time to antibiotics and time to the operating room may be more important than the particular antibiotic itself. Additionally, a recent study from 2015 looked at the organisms identified from culture results for Grade I through Grade III fractures in Germany. The vast majority of cultures obtained were gram positive organisms, even in the Grade III fractures, and included Staphylococcus epidermidis, Staphylococcus aureus, Staphylococcus capitis, various Streptococcus species, Enterococcus faecium and Corynebacterium. Interestingly, the only gram negative organism identified in the study was Escherichia coli. Lastly, when trying to identify antibiotic specific studies, a recent study was identified looking at Ceftriaxone as the agent of choice, while limiting the use of vancomycin and aminoglycosides. The conclusion of the study showed a significant decrease in vancomycin and aminoglycosides administered with no increase in infection rates. Here at St. Elizabeth Youngstown Hospital, the investigator's current trauma and orthopedics practice management guideline has been reviewed and changed multiple times in the past several years. For the vast majority of time, the recommendation has been to use the traditional cefazolin/gentamicin combination. However, several cases of nephrotoxicity led to some hesitation in utilizing this regimen. Therefore, for a short time period, piperacillin/tazobactam was being used for all Grade III fractures instead. At present however, due to conflicting concerns regarding antimicrobial stewardship with utilizing broad spectrum piperacillin/tazobactam with the nephrotoxicity concerns of gentamicin, the approved guideline utilizes cefazolin/gentamicin for patients under 65 years of age and piperacillin/tazobactam for all patients greater than or equal to 65 years of age. This study aims to evaluate non-inferiority of ampicillin/sulbactam, ceftriaxone, and piperacillin/tazobactam when compared to the traditional regimen of cefazolin/gentamicin for grade III open fractures.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Open Fracture, Post-Op Wound Infection
Keywords
Open Fracture, Wound Infection, Antimicrobial Prophylaxis, Cefazolin, Gentamicin, Ceftriaxone, Ampicillin/Sulbactam, Clindamycin, Piperacillin/tazobactam

7. Study Design

Primary Purpose
Prevention
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Model Description
Randomized, open-label
Masking
None (Open Label)
Allocation
Randomized
Enrollment
17 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Cefazolin + Gentamicin
Arm Type
Active Comparator
Arm Description
[Cefazolin] Initial dose: Cefazolin 2g IV x1 dose (patient weight < 120kg) Cefazolin 3g IV x1 dose (patient weight >/= 120kg) Subsequent dose: Cefazolin 2g IV every 8 hrs (CrCl >/= 40 mL/min) Cefazolin 2g IV every 12 hrs (CrCl 20-39 mL/min) Cefazolin 2g IV every 24 hrs (CrCl < 20 mL/min) Duration: 24 hrs post-op after soft tissue coverage or total of 72 hrs, whichever comes first [Gentamicin] Initial dose: If Patient age </= 80 years old: 5 mg/kg adjusted body weight x1 dose (Max dose 500 mg) If Patient age >80 years old: 3 mg/kg adjusted body weight x1 dose (Max dose 300 mg) Subsequent dose: Pharmacy Consult to dose gentamicin Duration: 24 hrs post-op after soft tissue coverage or total of 72 hrs, whichever comes first
Arm Title
Ceftriaxone
Arm Type
Active Comparator
Arm Description
Initial dose: Ceftriaxone 2g IV x1 dose Subsequent dose: Ceftriaxone 2g IV every 24 hours Duration: One dose post-op after soft tissue coverage or total of 72 hours, whichever comes first
Arm Title
Ampicillin/Sulbactam
Arm Type
Active Comparator
Arm Description
Initial dose: Ampicillin/Sulbactam 3g IV x1 dose Subsequent dose: Ampicillin/Sulbactam 3g IV every 6 hours (CrCl >/= 30 mL/min) Ampicillin/Sulbactam 3g IV every 12 hours (CrCl 15-29 mL/min) Ampicillin/Sulbactam 3g IV every 24 hours (CrCl <15 mL/min) Duration: 24 hours post-op after soft tissue coverage or total of 72 hours, whichever comes first
Arm Title
Piperacillin/Tazobactam
Arm Type
Active Comparator
Arm Description
Initial dose: Piperacillin/Tazobactam 4.5g IV x1 dose over 30 minutes Subsequent dose: Piperacillin/Tazobactam 3.375g IV every 8 hours over 4 hours (CrCl >/= 20 mL/min) Piperacillin/Tazobactam 3.375g IV every 12 hours over 4 hours (CrCl < 20 mL/min) Duration: 24 hours post-op after soft tissue coverage or total of 72 hours, whichever comes first
Arm Title
Clindamycin + Gentamicin
Arm Type
Other
Arm Description
Patients with known Penicillin allergy will receive: [Clindamycin] Initial dose: Clindamycin 900mg IV x1 dose Subsequent dose: Clindamycin 600mg IV every 8 hours Duration: 24 hours post-op after soft tissue coverage or total of 72 hours, whichever comes first [Gentamicin] Initial dose: If Patient age </= 80 years old: 5 mg/kg adjusted body weight x1 dose (Max dose 500 mg) If Patient age >80 years old: 3 mg/kg adjusted body weight x1 dose (Max dose 300 mg) Subsequent dose: Pharmacy Consult to dose gentamicin Duration: 24 hours post-op after soft tissue coverage or total of 72 hours, whichever comes first
Intervention Type
Drug
Intervention Name(s)
Ceftriaxone
Other Intervention Name(s)
Rocephin
Intervention Description
See arm description
Intervention Type
Drug
Intervention Name(s)
Ampicillin/sulbactam
Other Intervention Name(s)
Unasyn
Intervention Description
See arm description
Intervention Type
Drug
Intervention Name(s)
Piperacillin/tazobactam
Other Intervention Name(s)
Zosyn
Intervention Description
See arm description
Intervention Type
Drug
Intervention Name(s)
Cefazolin + Gentamicin
Other Intervention Name(s)
Ancef + Garamycin
Intervention Description
See arm description
Intervention Type
Drug
Intervention Name(s)
Clindamycin + Gentamicin
Other Intervention Name(s)
Cleocin + Garamycin
Intervention Description
See arm description
Primary Outcome Measure Information:
Title
Post-surgical site wound infections
Description
The primary outcome for this study is the number of post-surgical site wound infections, defined as initiation of antibiotics for surgical-site infection and/or need for surgical debridement of site. The acceptable infection rate per Trauma Practice Management Guidelines states a rate less than 20%.
Time Frame
1 year
Secondary Outcome Measure Information:
Title
Incidence of acute kidney injury
Description
Incidence of acute kidney injury during hospital admission will be collected and compared to the other antibiotic regimens. Acute kidney injury is defined as (per KDIGO guidelines): An increase in SCr by 0.3 mg/dL within 48 hours OR Increase in SCr to 1.5 times baseline within the previous 7 days OR Urine volume less than 0.5 mL/kg/h for 6 hours
Time Frame
Hospital admission
Title
Average cost of antibiotic therapy per patient
Description
Cost per patient of each antibiotic therapy will be calculated and compared to the other antibiotic regimens
Time Frame
Hospital admission
Title
Time to antibiotic therapy
Description
Time from arrival to receiving first dose of antibiotic therapy will be collected (Goal within 30 minutes of arrival).
Time Frame
Hospital admission

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Age great than/equal to 18 years Diagnosis of Grade III open fracture Exclusion Criteria: Water-borne injury Farm-related injury
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Natalie I Rine, PharmD
Organizational Affiliation
MercyHealth Youngstown
Official's Role
Study Chair
First Name & Middle Initial & Last Name & Degree
Paul T Miller, PharmD
Organizational Affiliation
MercyHealth Youngstown
Official's Role
Study Chair
First Name & Middle Initial & Last Name & Degree
Tyson T Schrickel, MD
Organizational Affiliation
MercyHealth Youngstown
Official's Role
Study Chair
First Name & Middle Initial & Last Name & Degree
Stuart Drew, DO
Organizational Affiliation
MercyHealth Youngstown
Official's Role
Study Chair
First Name & Middle Initial & Last Name & Degree
David J Gemmel, PhD
Organizational Affiliation
MercyHealth Youngstown
Official's Role
Study Chair
First Name & Middle Initial & Last Name & Degree
Chad W Donley, MD
Organizational Affiliation
MercyHealth Youngstown
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Allison R Lauver, PharmD
Organizational Affiliation
MercyHealth Youngstown
Official's Role
Study Chair
Facility Information:
Facility Name
St. Joseph Warren Hospital
City
Warren
State/Province
Ohio
ZIP/Postal Code
44484
Country
United States
Facility Name
St. Elizabeth Youngstown Hospital
City
Youngstown
State/Province
Ohio
ZIP/Postal Code
44501
Country
United States

12. IPD Sharing Statement

Plan to Share IPD
No
Citations:
PubMed Identifier
6471139
Citation
Gustilo RB, Mendoza RM, Williams DN. Problems in the management of type III (severe) open fractures: a new classification of type III open fractures. J Trauma. 1984 Aug;24(8):742-6. doi: 10.1097/00005373-198408000-00009.
Results Reference
background
PubMed Identifier
21610369
Citation
Hoff WS, Bonadies JA, Cachecho R, Dorlac WC. East Practice Management Guidelines Work Group: update to practice management guidelines for prophylactic antibiotic use in open fractures. J Trauma. 2011 Mar;70(3):751-4. doi: 10.1097/TA.0b013e31820930e5. No abstract available.
Results Reference
background
PubMed Identifier
25526095
Citation
Lack WD, Karunakar MA, Angerame MR, Seymour RB, Sims S, Kellam JF, Bosse MJ. Type III open tibia fractures: immediate antibiotic prophylaxis minimizes infection. J Orthop Trauma. 2015 Jan;29(1):1-6. doi: 10.1097/BOT.0000000000000262. Erratum In: J Orthop Trauma. 2015 Jun;29(6):e213.
Results Reference
background
PubMed Identifier
26542854
Citation
Otchwemah R, Grams V, Tjardes T, Shafizadeh S, Bathis H, Maegele M, Messler S, Bouillon B, Probst C. Bacterial contamination of open fractures - pathogens, antibiotic resistances and therapeutic regimes in four hospitals of the trauma network Cologne, Germany. Injury. 2015 Oct;46 Suppl 4:S104-8. doi: 10.1016/S0020-1383(15)30027-9.
Results Reference
background
PubMed Identifier
25159242
Citation
Rodriguez L, Jung HS, Goulet JA, Cicalo A, Machado-Aranda DA, Napolitano LM. Evidence-based protocol for prophylactic antibiotics in open fractures: improved antibiotic stewardship with no increase in infection rates. J Trauma Acute Care Surg. 2014 Sep;77(3):400-7; discussion 407-8; quiz 524. doi: 10.1097/TA.0000000000000398.
Results Reference
background
PubMed Identifier
20660225
Citation
Lenarz CJ, Watson JT, Moed BR, Israel H, Mullen JD, Macdonald JB. Timing of wound closure in open fractures based on cultures obtained after debridement. J Bone Joint Surg Am. 2010 Aug 18;92(10):1921-6. doi: 10.2106/JBJS.I.00547. Epub 2010 Jul 21.
Results Reference
background

Learn more about this trial

Noninferiority Comparison of Prophylactic Open Fracture Antimicrobial Regimens

We'll reach out to this number within 24 hrs